Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 67

1.

Antipsychotic medications and fertility.

Currier GW, Simpson GM.

Psychiatr Serv. 1998 Feb;49(2):175-6. Review. No abstract available.

PMID:
9575000
2.

Antipsychotic drug mechanisms and neurotransmitter systems in schizophrenia.

Reynolds GP.

Acta Psychiatr Scand Suppl. 1994;380:36-40. Review.

PMID:
7914046
3.

Review the role of dopamine D4 receptors in schizophrenia and antipsychotic action.

Sanyal S, Van Tol HH.

J Psychiatr Res. 1997 Mar-Apr;31(2):219-32. Review.

PMID:
9278187
4.

[Aripiprazole in the treatment of schizophrenia].

Bridler R.

Praxis (Bern 1994). 2005 Jun 8;94(23):975-7. German. No abstract available.

PMID:
16001540
5.

Positive findings for negative symptoms of schizophrenia: no longer untreatable?

Stahl SM.

Acta Psychiatr Scand. 2006 Nov;114(5):301-2. No abstract available.

PMID:
17022789
6.

Procedural learning in schizophrenia can reflect the pharmacologic properties of the antipsychotic treatments.

Scherer H, Bedard MA, Stip E, Paquet F, Richer F, Bériault M, Rodriguez JP, Motard JP.

Cogn Behav Neurol. 2004 Mar;17(1):32-40.

PMID:
15209223
7.

Plasma prolactin and central D2 receptor occupancy in antipsychotic drug-treated patients.

Nordström AL, Farde L.

J Clin Psychopharmacol. 1998 Aug;18(4):305-10.

PMID:
9690696
8.

The dopamine D4 receptor in schizophrenia: an update.

Kerwin RW, Collier D.

Psychol Med. 1996 Mar;26(2):221-7. Review. No abstract available.

PMID:
8685278
9.

[Dopamine D2 and serotonin 5HT2 receptors: functions, interactions and clinical consequences in schizophrenia].

Guise S, Soubrouillard C, Blin O.

Encephale. 1997 Apr;23 Spec No 2:10-6. Review. French.

PMID:
9273300
10.

Atypical antipsychotics: mechanism of action.

Seeman P.

Can J Psychiatry. 2002 Feb;47(1):27-38. Review.

PMID:
11873706
11.

A cross-sectional study of plasma risperidone levels with risperidone long-acting injectable: implications for dopamine D2 receptor occupancy during maintenance treatment in schizophrenia.

Ikai S, Remington G, Suzuki T, Takeuchi H, Tsuboi T, Den R, Hirano J, Tsunoda K, Nishimoto M, Watanabe K, Mimura M, Mamo D, Uchida H.

J Clin Psychiatry. 2012 Aug;73(8):1147-52. doi: 10.4088/JCP.12m07638.

PMID:
22967779
12.

Prospects for pharmacotherapy of schizophrenia.

Pickar D.

Lancet. 1995 Mar 4;345(8949):557-62. Review. No abstract available.

PMID:
7539875
13.

Prolactin awareness: an essential consideration for physical health in schizophrenia.

Montejo AL.

Eur Neuropsychopharmacol. 2008 May;18 Suppl 2:S108-14. doi: 10.1016/j.euroneuro.2008.02.004. Review.

PMID:
18346598
14.

Indirect modulation of dopamine D2 receptors as potential pharmacotherapy for schizophrenia: III. Retinoids.

Citver AS, Shields AM, Ciaccia LM, Schulingkamp RJ, Raffa RB.

J Clin Pharm Ther. 2002 Jun;27(3):161-8. Review.

PMID:
12081629
15.

Antipsychotic dosing: how much but also how often?

Remington G, Kapur S.

Schizophr Bull. 2010 Sep;36(5):900-3. doi: 10.1093/schbul/sbq083. Epub 2010 Jul 21. Review.

17.

High plasma prolactin levels after long-term neuroleptic treatment.

Zelaschi NM, Delucchi GA, Rodriguez JL.

Biol Psychiatry. 1996 May 15;39(10):900-1. No abstract available.

PMID:
8860193
18.

Abnormal prolactin elevation in a schizophrenic patient in treatment with quetiapine and mirtazapine. The role of opioid system.

Orlandi V, Speca A, Salviati M, Biondi M.

J Clin Psychopharmacol. 2003 Dec;23(6):677-9. No abstract available.

PMID:
14624206
19.

Aripiprazole treatment causes extrapyramidal side effects but not prolactin elevation: a disconnect of the striatal D2 occupancy story: case report.

Shim JC, You YS, Kelly DL.

J Clin Psychopharmacol. 2008 Jun;28(3):353-4. doi: 10.1097/JCP.0b013e31817279a6. No abstract available.

PMID:
18480699
20.

Supplemental Content

Support Center